Figure 3 | Scientific Reports

Figure 3

From: CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension

Figure 3

Therapeutic intervention of the CXCL12/CXCR4 signaling pathway in RNF213+/p.Arg4828Lys mice. (a) A CXC chemokine receptor type 4 (CXCR4) antagonist, AMD3100, was injected into RNF213+/p.Arg4828Lys mice fed in a hypoxic environment. The mRNA expressions of CXC motif chemokine ligand 12 (Cxcl12) (b) and forkhead box M1 (FoxM1) (c) were measured by real-time quantitative polymerase chain reaction. Body weight (d), right ventricular systolic pressure (RVSP) (e), and ratio of right ventricular weight to left ventricle plus septum weight [RV/(LV + S)] (f) were measured in each group. (g) Representative elastica van Gieson staining of lungs from rats in each experimental group. Scale bars: 20 μm. (h) Percent medial wall thickness (%MWT) in small pulmonary arteries (20–60 μm in diameter) was measured (n = 16 arteries from four mice per group). Statistically significant p-values are shown. Hx, hypoxia; NS, not significant.

Back to article page